Hikma Pharmaceuticals PLC (LON:HIK) Stock Has Average Price Target of GBX 2,085.83 According to Analysts

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have received a consensus rating of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is GBX 2,085.83.

Several research analysts recently issued reports on the stock. Berenberg Bank increased their price target on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,025 price objective on shares of Hikma Pharmaceuticals in a report on Friday, September 25th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Finally, Citigroup increased their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Tobias Hestler acquired 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Stock Down 2.9%

HIK stock opened at GBX 1,571 on Tuesday. Hikma Pharmaceuticals has a one year low of GBX 1,187 and a one year high of GBX 1,865. The stock has a market capitalization of £3.25 billion, a PE ratio of 8.93, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. The company has a fifty day moving average of GBX 1,606.70 and a 200-day moving average of GBX 1,488.94.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.